Kluwer Patent Blog

Vericore v. The Danish Board of Appeals, Maritime and Commercial Court (Højesteret), 24 January 2012

Anders Valentin (Bugge Valentin) · Tuesday, May 29th, 2012

The Danish Maritime and Commercial Court upheld the invalidation (in two administrative instances) of a patent claiming second medical use of a known compound for the treatment of sea lice infestation on the grounds that neither the pathology nor the patient group were novel over the closest prior art. The European sister patent had likewise been invalidated by the EPO Technical Board of Appeal (T 0708/02).

A summary of this case will be posted on http://www.KluwerIPCases.com

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Tuesday, May 29th, 2012 at 5:28 pm and is filed under Case Law, Denmark, Novelty, Second Medical Use, Validity

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.